PF 06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
Shahrzad Moosavi
Troy Borema
Reginald Ewesuedo
Stuart Harris
Jeffrey Levy
Thomas B. May
Martin Summers
Jeffrey S. Thomas
Jeffrey Zhang
Hsuan-Ming Yao
10.6084/m9.figshare.12280886.v1
https://adisjournals.figshare.com/articles/figure/PF_06881894_a_Proposed_Biosimilar_to_Pegfilgrastim_Versus_US-Licensed_and_EU-Approved_Pegfilgrastim_Reference_Products_Neulasta_Pharmacodynamics_Pharmacokinetics_Immunogenicity_and_Safety_of_Single_or_Multiple_Subcutaneous_Doses_in_Healthy_/12280886
<p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020.<b> </b></p>
2020-05-28 12:10:44
Biosimilar
Immunogenicity
Myelosuppressive chemotherapy
Neulasta®
Neutropenia
Pegfilgrastim
PF-06881894
Pharmacodynamics
Pharmacokinetics
Safety